Epac2 in midbrain dopamine neurons contributes to cocaine reinforcement via facilitation of dopamine release

Abstract

Repeated exposure to drugs of abuse results in an upregulation of cAMP signaling in the mesolimbic dopamine system, a molecular adaptation thought to be critically involved in the development of drug dependence. Exchange protein directly activated by cAMP (Epac2) is a major cAMP effector abundantly expressed in the brain. However, it remains unknown whether Epac2 contributes to cocaine reinforcement. Here, we report that Epac2 in the mesolimbic dopamine system promotes cocaine reinforcement via enhancement of dopamine release. Conditional knockout of Epac2 from midbrain dopamine neurons (Epac2-cKO) and the selective Epac2 inhibitor ESI-05 decreased cocaine self-administration in mice under both fixed-ratio and progressive-ratio reinforcement schedules and across a broad range of cocaine doses. In addition, Epac2-cKO led to reduced evoked dopamine release, whereas Epac2 agonism robustly enhanced dopamine release in the nucleus accumbens in vitro. This mechanism is central to the behavioral effects of Epac2 disruption, as chemogenetic stimulation of ventral tegmental area (VTA) dopamine neurons via deschloroclozapine (DCZ)-induced activation of Gs-DREADD increased dopamine release and reversed the impairment of cocaine self-administration in Epac2-cKO mice. Conversely, chemogenetic inhibition of VTA dopamine neurons with Gi-DREADD reduced dopamine release and cocaine self-administration in wild-type mice. Epac2-mediated enhancement of dopamine release may therefore represent a novel and powerful mechanism that contributes to cocaine reinforcement.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting file; Source Data files have been provided for figures 1-7. Custom code used for the analysis of the fiber photometry data is available at https://github.com/xiaojieliu17/Fiber-photometry.

Article and author information

Author details

  1. Xiaojie Liu

    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Casey R Vickstrom

    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Hao Yu

    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Shuai Liu

    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Shana Terai Snarrenberg

    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Vladislav Friedman

    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Lianwei Mu

    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Bixuan Chen

    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Thomas J Kelly

    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. David A Baker

    Department of Biomedical Sciences, Marquette University, Milwaukee, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Qing-song Liu

    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, United States
    For correspondence
    qsliu@mcw.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1858-1504

Funding

National Institute on Drug Abuse (R01DA035217)

  • Qing-song Liu

National Institute on Drug Abuse (R01DA047269)

  • Qing-song Liu

National Institute of Mental Health (F30MH115536)

  • Casey R Vickstrom

National Institute on Drug Abuse (R01DA050180)

  • David A Baker

National Institute on Drug Abuse (F31DA054759)

  • Vladislav Friedman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal maintenance and use were in accordance with protocols (AUA #2420) approved by the Institutional Animal Care and Use Committee of Medical College of Wisconsin. All surgery was performed under ketamine and xylazine anesthesia, and every effort was made to minimize suffering.

Copyright

© 2022, Liu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,437
    views
  • 299
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xiaojie Liu
  2. Casey R Vickstrom
  3. Hao Yu
  4. Shuai Liu
  5. Shana Terai Snarrenberg
  6. Vladislav Friedman
  7. Lianwei Mu
  8. Bixuan Chen
  9. Thomas J Kelly
  10. David A Baker
  11. Qing-song Liu
(2022)
Epac2 in midbrain dopamine neurons contributes to cocaine reinforcement via facilitation of dopamine release
eLife 11:e80747.
https://doi.org/10.7554/eLife.80747

Share this article

https://doi.org/10.7554/eLife.80747

Further reading

    1. Developmental Biology
    2. Neuroscience
    Sebastián Giunti, María Gabriela Blanco ... Diego Rayes
    Research Article

    A finely tuned balance between excitation and inhibition (E/I) is essential for proper brain function. Disruptions in the GABAergic system, which alter this equilibrium, are a common feature in various types of neurological disorders, including autism spectrum disorders (ASDs). Mutations in Phosphatase and Tensin Homolog (PTEN), the main negative regulator of the phosphatidylinositol 3-phosphate kinase/Akt pathway, are strongly associated with ASD. However, it is unclear whether PTEN deficiencies can differentially affect inhibitory and excitatory signaling. Using the Caenorhabditis elegans neuromuscular system, where both excitatory (cholinergic) and inhibitory (GABAergic) inputs regulate muscle activity, we found that daf-18/PTEN mutations impact GABAergic (but not cholinergic) neurodevelopment and function. This selective impact results in a deficiency in inhibitory signaling. The defects observed in the GABAergic system in daf-18/PTEN mutants are due to reduced activity of DAF-16/FOXO during development. Ketogenic diets (KGDs) have proven effective for disorders associated with E/I imbalances. However, the mechanisms underlying their action remain largely elusive. We found that a diet enriched with the ketone body β-hydroxybutyrate during early development induces DAF-16/FOXO activity, therefore improving GABAergic neurodevelopment and function in daf-18/PTEN mutants. Our study provides valuable insights into the link between PTEN mutations and neurodevelopmental defects and delves into the mechanisms underlying the potential therapeutic effects of KGDs.

    1. Neuroscience
    Chen Wang, Berta Vidal ... Oliver Hobert
    Tools and Resources

    Mapping neurotransmitter identities to neurons is key to understanding information flow in a nervous system. It also provides valuable entry points for studying the development and plasticity of neuronal identity features. In the Caenorhabditis elegans nervous system, neurotransmitter identities have been largely assigned by expression pattern analysis of neurotransmitter pathway genes that encode neurotransmitter biosynthetic enzymes or transporters. However, many of these assignments have relied on multicopy reporter transgenes that may lack relevant cis-regulatory information and therefore may not provide an accurate picture of neurotransmitter usage. We analyzed the expression patterns of 16 CRISPR/Cas9-engineered knock-in reporter strains for all main types of neurotransmitters in C. elegans (glutamate, acetylcholine, GABA, serotonin, dopamine, tyramine, and octopamine) in both the hermaphrodite and the male. Our analysis reveals novel sites of expression of these neurotransmitter systems within both neurons and glia, as well as non-neural cells, most notably in gonadal cells. The resulting expression atlas defines neurons that may be exclusively neuropeptidergic, substantially expands the repertoire of neurons capable of co-transmitting multiple neurotransmitters, and identifies novel sites of monoaminergic neurotransmitter uptake. Furthermore, we also observed unusual co-expression patterns of monoaminergic synthesis pathway genes, suggesting the existence of novel monoaminergic transmitters. Our analysis results in what constitutes the most extensive whole-animal-wide map of neurotransmitter usage to date, paving the way for a better understanding of neuronal communication and neuronal identity specification in C. elegans.